Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.
Euro Surveill
; 27(33)2022 08.
Article
in English
| MEDLINE | ID: covidwho-2002443
ABSTRACT
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR)â¯=â¯0.08; 95% confidence interval (CI) 0.05-0.13) but not with anti-S antibodies (aORâ¯=â¯1.06; 95% CI 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Antibodies, Viral
Type of study:
Observational study
/
Prognostic study
Topics:
Variants
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
1560-7917.ES.2022.27.33.2200619
Similar
MEDLINE
...
LILACS
LIS